Population pharmacokinetics of the novel anticancer agent KRN7000

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 4, 2002, Pages 287-293

  Crul, Mirjam ^a,b,c,d,e,f   Mathôt, Ron A ^a,b,c,d,e,f   Giaccone, Giuseppe ^a,b,c,d,e,f   Punt, Cornelis J ^a,b,c,d,e,f   Rosing, Hilde ^a,b,c,d,e,f   Hillebrand, Michel J ^a,b,c,d,e,f   Ando, Yoshitaka ^a,b,c,d,e,f   Nishi, Nobosuke ^a,b,c,d,e,f   Tanaka, Hideji ^a,b,c,d,e,f   Schellens, Jan H ^a,b,c,d,e,f   Beijnen, Jos H ^a,b,c,d,e,f  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e KIRIN BREWERY CO LTD   (Japan)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

KRN7000; Model building; Model validation; NONMEM; Population pharmacokinetics

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOSTIMULATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VALIDATION PROCESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GALACTOSYLCERAMIDES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 0036209763     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0413-3     Document Type: Article

References (13)

1. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors
2. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells
3. Xpose - An S-PLUS based population pharmacokinetic-pharmacodynamic model building aid for NONMEM
4. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides
5. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans
6. Building population pharmacokinetic models. I. Models for covariate effects
7. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice
8. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice
9. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000
10. + T cells in vitro
11. Population pharmacokinetics. A regulatory perspective
12. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexa-cosanoylamino)-1,3,4- octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimeta-static activity of KRN7000-pretreated antigen-presenting cells